Dr. Reddy’s Laboratories has introduced Toripalimab (brand name Zytorvi), a next-generation PD-1 inhibitor, for treating recurrent or metastatic nasopharyngeal carcinoma (NPC). This marks India as the third country after China and the United States to access this immuno-oncology drug.
The medication is approved for first-line treatment in combination with chemotherapy, showing a 48% reduction in disease progression or death risk. According to GLOBOCAN 2022, India reported 6,519 new NPC cases in 2022, with the highest incidence in northeastern states.
Dr. Reddy’s obtained exclusive rights to develop and commercialize Toripalimab in 21 countries through a license agreement with Shanghai Junshi Biosciences, highlighting the company’s commitment to expanding oncology treatment options in emerging markets.
